Incyte Corporation [NASDAQ: INCY] closed the trading session at $84.95 on 11/03/20. The day’s price range saw the stock hit a low of $83.93, while the highest price level was $86.165. The company report on November 3, 2020 that ACR 2020: Lilly and Incyte Highlight Positive Data for Olumiant® in Rheumatoid Arthritis.
Latest long-term safety and efficacy data on Olumiant reinforce the medicine’s potential to help people living with rheumatoid arthritis (RA).
Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today positive data for Olumiant® (baricitinib) will be presented at ACR Convergence 2020, the American College of Rheumatology’s virtual annual meeting taking place November 5-9, 2020. The Olumiant data being presented at this year’s meeting include new long-term studies in adult patients living with rheumatoid arthritis (RA), along with real-world evidence (RWE) on safety and efficacy.
The stocks have a year to date performance of -2.71 percent and weekly performance of -3.85 percent. The stock has been moved at -11.58 percent over the last six months. The stock has performed -7.96 percent around the most recent 30 days and changed -12.98 percent over the most recent 3-months.
If compared to the average trading volume of 1.11M shares, INCY reached to a volume of 1061930 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Incyte Corporation [INCY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for INCY shares is $106.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on INCY stock is a recommendation set at 2.30. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Benchmark Company have made an estimate for Incyte Corporation shares, keeping their opinion on the stock as Hold, with their previous recommendation back on June 16, 2020. While these analysts kept the previous recommendation, JP Morgan raised their target price from $89 to $99. The new note on the price target was released on May 06, 2020, representing the official price target for Incyte Corporation stock. Previously, the target price had yet another raise to $94, while Morgan Stanley analysts kept a Equal-Weight rating on INCY stock. On April 01, 2020, analysts increased their price target for INCY shares from 83 to 90.
The Average True Range (ATR) for Incyte Corporation is set at 3.05, with the Price to Sales ratio for INCY stock in the period of the last 12 months amounting to 7.82. The Price to Book ratio for the last quarter was 7.88, with the Price to Cash per share for the same quarter was set at 7.24.
INCY stock trade performance evaluation
Incyte Corporation [INCY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.85. With this latest performance, INCY shares dropped by -7.96% in over the last four-week period, additionally sinking by -11.58% over the last 6 months – not to mention a rise of 0.62% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for INCY stock in for the last two-week period is set at 39.83, with the RSI for the last a single of trading hit 34.64, and the three-weeks RSI is set at 42.07 for Incyte Corporation [INCY]. The present Moving Average for the last 50 days of trading for this stock 90.32, while it was recorded at 86.01 for the last single week of trading, and 90.34 for the last 200 days.
Incyte Corporation [INCY]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Incyte Corporation [INCY] shares currently have an operating margin of +19.53 and a Gross Margin at +93.18. Incyte Corporation’s Net Margin is presently recorded at +20.70.
Return on Total Capital for INCY is now 18.28, given the latest momentum, and Return on Invested Capital for the company is 19.49. Return on Equity for this stock inclined to 19.76, with Return on Assets sitting at 14.72. When it comes to the capital structure of this company, Incyte Corporation [INCY] has a Total Debt to Total Equity ratio set at 2.77. Additionally, INCY Total Debt to Total Capital is recorded at 2.70, with Total Debt to Total Assets ending up at 2.10. Long-Term Debt to Equity for the company is recorded at 1.68, with the Long-Term Debt to Total Capital now at 1.64.
Reflecting on the efficiency of the workforce at the company, Incyte Corporation [INCY] managed to generate an average of $306,941 per employee. Receivables Turnover for the company is 7.00 with a Total Asset Turnover recorded at a value of 0.71.Incyte Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.70 and a Current Ratio set at 3.70.
Earnings per share (EPS) analysis for Incyte Corporation [INCY] stock
With the latest financial reports released by the company, Incyte Corporation posted 0.82/share EPS, while the average EPS was predicted by analysts to be reported at 0.65/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 26.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for INCY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Incyte Corporation go to 25.94%.
Incyte Corporation [INCY]: Insider Ownership positions
There are presently around $17,557 million, or 98.00% of INCY stock, in the hands of institutional investors. The top three institutional holders of INCY stocks are: BAKER BROS. ADVISORS LP with ownership of 31,999,081, which is approximately 0.063% of the company’s market cap and around 0.50% of the total institutional ownership; PRICE T ROWE ASSOCIATES INC /MD/, holding 29,548,923 shares of the stock with an approximate value of $2.51 billion in INCY stocks shares; and VANGUARD GROUP INC, currently with $1.76 billion in INCY stock with ownership of nearly 0.728% of the company’s market capitalization.
Positions in Incyte Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 241 institutional holders increased their position in Incyte Corporation [NASDAQ:INCY] by around 21,690,065 shares. Additionally, 263 investors decreased positions by around 15,060,815 shares, while 64 investors held positions by with 169,926,579 shares. The mentioned changes placed institutional holdings at 206,677,459 shares, according to the latest SEC report filing. INCY stock had 70 new institutional investments in for a total of 1,065,677 shares, while 73 institutional investors sold positions of 2,482,747 shares during the same period.